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Editorial
Intravenous administration of interleukin-2 (IL-2) is a useful
therapy for stage IV melanoma and renal cell cancer, stimu-
lating proliferation of T cells, lymphocyte activated killer
cells, natural killer cells and other immune effectors, which
then target and eliminate cancer cells. In about 15 % of pa-
tients, tumor burden is significantly lessened and complete
cure is seen in 6 - 8 %.1-3 However, IL-2 therapy can cause
severe side effects including pulmonary edema, psychosis,
renal failure, hepatitis and myocardial infarctions.3 The
treatment protocols basically simulate septic shock to get an
immune response against cancer. Patients have to pass a car-
diac stress test before starting IL-2, and as a result many pa-
tients are precluded from even starting IL-2 therapy. Those
medically cleared for the grueling protocol undergo inten-
sive care level monitoring while receiving IL-2 infusions.
Even for patients able to tolerate IL-2 therapy without per-
manent harm, almost always the number of doses given in
any cycle is well below the optimal amount because of pa-
tients start showing unacceptable side effects. I personally
have had the experience of patients experiencing severe
shaking rigors, at the very threshold of threatened end organ
damage, yet desperately pleading for just one more dose of
IL-2, to get just that much more chance of disease-free sur-
vival.  Those desperate patients prompt me to propose to
this audience that we should consider reviving the old idea
of administering IL-2 into the splenic artery instead of the
systemic circulation.
The concept of splenic artery infusion of IL-2 for cancer
immunotherapy goes back over a quarter of a century, but
new efforts are needed. The basic premise, validated in data
so far, is that you need far smaller amounts of intrasplenical-
ly infused IL-2 to get maximum immune response, and most,
if not all, of the IL-2 has its action within the spleen rather
than the systemic circulation. The spleen gives rise to 25 %
of total circulating T lymphocytes and 10 - 15 % of B lym-
phocytes, and about 50 % of all lymphocytes in the body are
thought to pass through the splenic arterioles in the course
of their lifetime. The spleen receives 100 % of its arterial
blood supply from the splenic artery, making percutaneous
access relatively easy. Pilot testing of splenic artery infusion
of IL-2 first took place in mouse models in the mid 1980’s.4
Subsequently in 1990, 20 patients with stage IV renal cell
cancer, melanoma and lymphoma underwent a phase I clin-
ical trial with low dose IL-2 continuously infused over 5
consecutive days at 3 weeks intervals for 2 - 4 cycles via a
splenic arterial catheter placed through the femoral artery.5
Each patient received from 90,000 - 240,000 IU/kg/day for a
total dose of 450,000-1.2 millionIU/kg/cycle, much lower
than the maximum dose of 8.4 million IU/kg/cycle with cur-
rent systemic IL-2. In 3 of the 20 patients, visible reduction
of tumor burden could be demonstrated. Two patients with
renal cell cancer had complete regression of hepatic metas-
tases, while primary tumor and other extra-renal metastases
were unchanged. A third patient one with non-Hodgkin’s
lymphoma, had 40 % reduction of total tumor within lymph
nodes. All of the patients in the study had measurable in-
creases in natural killer cells and lymphocyte activated killer
cells, and none of the 20 patients had any known side ef-
fects.5
In addition to the above study, in the 1990’s there were small
open trials of splenic IL-2 for stage IV melanoma, colorectal
cancer and pancreatic cancer metastatic to the liver; these
protocols also gave IL-2 via the hepatic artery and some of
them also gave other chemotherapy or infused activated
natural cells back into the hepatic artery.6-13 Access of the
splenic artery was surgical rather than percutaneous. In all of
these trials there appeared to be clinical benefit without
undue adverse reactions. To the best of my knowledge, these
are the most recent clinical trials of splenic artery infusion of
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IL-2, but there have been more recent case reports of pa-
tients getting splenic artery infusion of chemotherapy for
myelofibrosis14, which confirms that the technology for
splenic artery infusion of IL-2 remains current.
Furthermore, in 1992 there was a published series of 51 pa-
tients who underwent splenic artery catheterization specifi-
cally to infuse IL-2, providing a benchmark of expected
safety.15 In this series, the rate of complications from splenic
artery catheterization was fairly low, with 4.5 % of patients
having subintimal contrast injection, 2.3 % having bleeding
and hematoma and with a mortality from the procedure of
0 % (one patient had cardiac arrest from IL-2 infusion rather
than splenic artery catheterization and this patient was suc-
cessfully resuscitated).15 The one limitation of this study is
that patients received both splenic and intravenous infusions
of IL-2 at different time points, and so patients too medically
frail for intravenous IL-2 were not included. Still, it provides
a useful guidepost for new research protocols.
I am working under the assumption that splenic artery IL-2
will be delivered via an indwelling percutaneous catheter
placed by an interventional radiologist, rather than via sur-
gical exposure of the splenic artery. The former is obviously
less expensive, less invasive and requires much less time for
recovery. An analogy is that patients who have percutaneous
coronary angioplasty and stenting spend much less time in
the hospital compared those who have coronary artery by-
pass grafting surgery.  Moving forward, efficacy of splenic
IL-2 should be confirmed both with animal models and clin-
ical trials. An excellent model system for metastatic mela-
noma exists in the formof a strain of Sinclair swine that de-
velop a hereditary metastatic melanoma.16-19 In 85-95 % of
the melanoma bearing Sinclair swine, there is complete
spontaneous regression of the melanomas by young adult-
hood (8 months old) through both immune mediated mech-
anisms as well as natural differentiation and preprogrammed
apoptosis. Those pigs unable to clear melanoma on their own
would be an ideal experimental system for infusing splenic
IL-2. For clinical trials, a logical place to start would be with
stage IV melanoma and renal cell cancer who are failing IL-2
protocols due to intolerance of side effects or lack of tumor
regression. For both animal and clinical studies, the aim
should be the same: quantitative proof that splenic artery
IL-2 can achieve greater biological effect against metastatic
stage IV cancer with less or no systemic side effects. For
clinical trials, another important aim should be to prove that
patients ineligible for systemic IL-2 due to medical comor-
bidities can tolerate splenic IL-2 infusions without problems.
Latter day success with splenic IL-2 could provide new op-
tions and better outcomes for patients with untreatable met-
astatic melanoma, renal cell cancer and other malignancies.
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